A STUDY OF EVEROLIMUS PLUS EXEMESTANE IN CHINESE POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE, LOCALLY ADVANCED, RECURRENT, OR METASTATIC BREAST CANCER AFTER RECURRENCE OR PROGRESSION ON NON-STEROIDAL AROMATASE INHIBITOR: